The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

The company disclosed revenue of $13.7 billion and adjusted earnings of $0.92 per share, compared to consensus estimates of ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research ...

Pfizer said it still expects adjusted 2025 profit of $2.80 a share to $3 a share, while analysts expect full-year earnings of $2.94 a share. Pfizer also projected 2025 revenue of $61 billion to $64 ...

Novavax said Monday that the Food and Drug Administration was asking the company to run a new clinical trial of its vaccine.

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, “which we are unable ...